InsiderTrades.com logo

ENTX Insider Trading

Insider Ownership Percentage: 10.38%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Entera Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Entera Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Entera Bio Share Price & Price History

Current Price: $2.11
Price Change: ▲ Price Increase of +0.05 (2.43%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for ENTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Entera Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2024Haya TaitelDirectorBuy9,500$0.99$9,405.0035,115View SEC Filing Icon  
1/10/2024Haya TaitelDirectorBuy7,615$0.77$5,863.5525,615View SEC Filing Icon  
12/22/2023Miranda Jayne ToledanoCEOBuy23,952$0.71$17,005.92110,752View SEC Filing Icon  
8/21/2023Sean EllisDirectorBuy40,000$0.60$24,000.00102,100View SEC Filing Icon  
4/4/2023Miranda Jayne ToledanoCEOBuy30,000$1.01$30,300.0086,800View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Entera Bio (NASDAQ:ENTX)

14.11% of Entera Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ENTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Entera Bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/17/2025Parkman Healthcare Partners LLC280,822$0.54M0.1%-21.1%0.615%Search for SEC Filing on Google Icon
11/17/2025Citadel Advisors LLC39,978$77K0.0%+243.0%0.088%Search for SEC Filing on Google Icon
11/14/2025Schonfeld Strategic Advisors LLC566,956$1.09M0.0%-6.2%1.242%Search for SEC Filing on Google Icon
8/15/2025Bank of America Corp DE23,430$45K0.0%-24.4%0.051%Search for SEC Filing on Google Icon
8/1/2025Bessemer Group Inc.140,843$0.27M0.0%N/A0.310%Search for SEC Filing on Google Icon
5/16/2025Parkman Healthcare Partners LLC439,632$0.75M0.1%+6.3%0.968%Search for SEC Filing on Google Icon
5/13/2025HighTower Advisors LLC18,140$31K0.0%+53.3%0.040%Search for SEC Filing on Google Icon
2/18/2025Knoll Capital Management LLC5,881,879$12.47M8.0%+51.5%16.439%Search for SEC Filing on Google Icon
2/14/2025Schonfeld Strategic Advisors LLC632,311$1.34M0.0%-2.5%1.767%Search for SEC Filing on Google Icon
2/14/2025Northern Trust Corp212,483$0.45M0.0%N/A0.594%Search for SEC Filing on Google Icon
1/22/2025Perigon Wealth Management LLC145,843$0.33M0.0%N/A0.408%Search for SEC Filing on Google Icon
11/15/2024Parkman Healthcare Partners LLC411,076$0.78M0.1%+2.4%1.149%Search for SEC Filing on Google Icon
11/6/2024Signature Estate & Investment Advisors LLC47,328$90K0.0%N/A0.132%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC57,600$0.11M0.0%-23.1%0.161%Search for SEC Filing on Google Icon
5/20/2024Virtu Financial LLC22,040$37K0.0%N/A0.000%Search for SEC Filing on Google Icon
2/14/2023RA Capital Management L.P.295,966$0.22M0.0%-85.8%1.028%Search for SEC Filing on Google Icon
11/14/2022RA Capital Management L.P.2,082,372$2.17M0.0%-11.5%7.229%Search for SEC Filing on Google Icon
1/31/2022Altium Wealth Management LLC11,830$33K0.0%N/A0.050%Search for SEC Filing on Google Icon
1/28/2022ARK Investment Management LLC690,922$1.95M0.0%+1.2%2.915%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Entera Bio logo
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Read More on Entera Bio

Today's Range

Now: $2.11
Low: $2.07
High: $2.25

50 Day Range

MA: $2.45
Low: $1.82
High: $3.14

52 Week Range

Now: $2.11
Low: $1.50
High: $3.22

Volume

94,078 shs

Average Volume

76,997 shs

Market Capitalization

$96.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Who are the company insiders with the largest holdings of Entera Bio?

Entera Bio's top insider shareholders include:
  1. Miranda Jayne Toledano (CEO)
  2. Haya Taitel (Director)
Learn More about top insider investors at Entera Bio.

Who are the major institutional investors of Entera Bio?

Entera Bio's top institutional investors include:
  1. Schonfeld Strategic Advisors LLC — 1.24%
  2. Parkman Healthcare Partners LLC — 0.62%
  3. Citadel Advisors LLC — 0.09%
Learn More about top institutional investors of Entera Bio stock.

Which major investors are selling Entera Bio stock?

Within the last quarter, ENTX stock was sold by these institutional investors:
  1. Parkman Healthcare Partners LLC
  2. Schonfeld Strategic Advisors LLC

Which major investors are buying Entera Bio stock?

During the last quarter, ENTX stock was bought by institutional investors including:
  1. Citadel Advisors LLC
In the last year, these company insiders have bought Entera Bio stock:
  1. Miranda Jayne Toledano (CEO)
  2. Haya Taitel (Director)
Learn More investors buying Entera Bio stock.